Futura Medical plc announced that it has appointed a clinical research organisation (CRO) to conduct its forthcoming clinical efficacy study on MED2002, the Company's topical gel for the treatment of erectile dysfunction (ED). The study, which will take place in the UK, is expected to commence in first quarter of 2015 and report in fourth quarter of 2015. The CRO for this study is the same CRO that conducted the successful pivotal study for CSD500, the Company's novel condom which launched several months ago and shares the same active ingredient as MED2002.

In contrast to CSD500, MED2002 is expected initially to be a prescription-only product. Approximately 140 patients with ED will participate in the study, which will be a randomised, placebo-controlled, double blind, home use, cross-over design. The primary outcome of the study is statistically significant efficacy.